HCPLive Network

Osteoporosis Therapy Has Unclear Impact on Spinal Fusion

FRIDAY, March 1 (HealthDay News) -- The effect of osteoporosis therapies (bisphosphonate drugs and intermittent parathyroid hormone [PTH]) on spinal fusion is unclear, according to a review published in the February issue of The Spine Journal.

Brandon P. Hirsch, MD, of the University of Miami/Jackson Health System, and colleagues conducted a systematic review of the literature from 1980 to 2011 to assess the potential impact of bisphosphonates and PTH on fusion rate and quality in spinal arthrodesis. Eighteen animal studies and one clinical trial were included in the review.

The researchers found that most animal studies showed that bisphosphonates have no significant impact on fusion rate but that treatment may result in less histologically mature fusion mass; the impact of these changes on fusion mass biomechanics was unclear. Based on the human study, bisphosphonates had no impact on clinical outcome but may have increased the radiographically defined fusion rate. PTH improved the fusion rate and fusion mass microstructure in animals, but data were lacking for the effect on fusion mass biomechanics. There were no studies that assessed the impact of PTH on spine mass in humans.

"In the absence of conclusive human data relating to spine fusion, we recommend the continuation or initiation of these therapies in patients based on their indication for the treatment of osteoporosis, without regard for a recent or impending spine fusion procedure," the authors write. "However, on the basis of preclinical data, we believe that anabolic agents may offer an advantage over antiresorptive medications in osteoporotic patients undergoing spine fusion."

One author disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
App will help patients with diabetes log their hypoglycemic events and achieve better control of these events by becoming more aware of preceding signs and symptoms.
Provocative research raises the question of whether we should we look at Alzheimer’s disease as “type 3 diabetes.”
Presentation at CMHC 2014 provides updates on emerging classes of diabetes treatment, including preliminary data from current clinical trials.
In remarks delivered at the American Academy of Family Physicians 2014 Assembly, HHS Secretary Sylvia Mathews Burwell spoke about the ongoing response to the Ebola outbreak, improving health care delivery, the Affordable Care Act, and the Transforming Clinical Practice Initiative.
Seniors who wear their dentures when they sleep are at increased risk for pneumonia, according to a study published online Oct. 7 in the Journal of Dental Research.
A pattern of sleep disturbance is a risk factor for depression and suicide and also increases the risk of cancer, infection, hypertension, weight gain, heart disease, diabetes, inflammation, osteoporosis, chronic pain, and arrhythmias. It can also have a significant negative impact on cognition and creativity.
For stroke survivors, annual direct costs are comparable at 10 years and between 3 to 5 years for ischemic stroke but are higher at 10 years after hemorrhagic stroke, according to a study published online Oct. 23 in Stroke.
More Reading